NKAPL: A Potential Drug Target and Biomarker for Nuclear Factor Kappa B (NFKB) Activating Protein

Target Name: NKAPL

NCBI ID: G222698

NKAPL

NKAPL: A Potential Drug Target and Biomarker for Nuclear Factor Kappa B (NFKB) Activating Protein

Introduction

Nuclear factor kappa B (NFKB) is a crucial transcription factor that plays a significant role in regulating various cellular processes, including inflammation, cell survival, and cell-cell communication. Activating transcription factor A1 (ATF-A1) and its adapter protein, NKAPL (NFKB activating protein like), are key components of the NFKB signaling pathway. The NKAPL gene has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.

NKAPL: Structure and Function

NKAPL is a 21-kDa protein that belongs to the NFKB signaling pathway. It is composed of a 166 amino acid residue protein tail and a 156 amino acid residue protein N-terminus. The protein tail contains a putative N-terminal transmembrane domain and a series of conserved putative transmembrane domains, including a dopamine-containing putative tyrosine kinase domain, a potential N-terminal coiled-coil domain, and a putative cytoplasmic domain.

NKAPL functions as an adapter protein for the NFKB signaling pathway. It interacts with the NFKB core protein, which is a 29 kDa protein that consists of a N-terminal transmembrane domain, a catalytic domain, and a C-terminal DNA-binding domain ( 2). The NKAPL protein provides a critical link between the NFKB core protein and various DNA-bound transcription factors, allowing for the recruitment of NFKB-regulated genes to the nucleus.

NKAPL has been shown to play a crucial role in various biological processes, including inflammation, cell survival, and cell-cell communication. For example, NKAPL has been shown to promote the NFKB signaling pathway in response to oxidative stress, and it has been linked to the development of neurodegenerative disorders. Additionally, NKAPL has been shown to contribute to the regulation of cell cycle progression, apoptosis, and cell survival.

Drug Targeting and Biomarker Potential

The NKAPL gene has been identified as a potential drug target for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. The ability of NKAPL to regulate the NFKB signaling pathway makes it an attractive target for small molecule inhibitors that can modulate NFKB activity.

One of the most promising NKAPL-targeted small molecules is a chemical compound, WQ1, which is a potent inhibitor of the NKAPL-NFKB signaling pathway. WQ1 inhibits the NKAPL-NFKB complex at the level of protein interaction, leading to a decrease in NFKB-mediated gene expression and cell proliferation.

In addition to its potential as a drug target, NKAPL has also been identified as a potential biomarker for various diseases. The NKAPL gene has been shown to be expressed in various tissues and cells, including brain, spleen, and peripheral blood cells. Additionally, NKAPL has been shown to be involved in the regulation of cellular processes, including cell cycle progression, apoptosis, and inflammation.

Conclusion

In conclusion, NKAPL is a protein that plays a crucial role in the NFKB signaling pathway. Its ability to regulate the NFKB signaling pathway makes it an attractive target for small molecule inhibitors that can modulate NFKB activity. Additionally, NKAPL has been shown to be involved in various cellular processes, including cell cycle progression, apoptosis, and inflammation, making it a potential biomarker for various diseases. Further research is needed to fully understand the role of NKAPL in

Protein Name: NFKB Activating Protein Like

Functions: Transcriptional repressor of Notch-mediated signaling. Required for spermatogenesis

The "NKAPL Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NKAPL comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets